Lappuse 1 no 17 rezultātiem
The effect of taxol, which is a microtubule stabilizer, was examined in a model of acute edematous pancreatitis induced in rat by the administration of caerulein. Prophylactic administration of taxol ameliorated inhibition of pancreatic secretion, increased level of serum amylase, pancreatic edema,
Effects of colchicine, a microtubule-disrupting agent, on rate exocrine pancreas were examined in comparison with the microtubule stabilizer Taxol for the purpose of analyzing the pathogenesis of cerulein-induced acute pancreatitis. Taxol ameliorated the inhibition of pancreatic secretion, elevation
OBJECTIVE
Paclitaxel (Taxol) is a microtubule-stabilizing agent and belongs to the taxane group of chemotherapeutic drugs. It is used to treat numerous malignancies, such as breast and lung cancers. A rare side effect of this drug includes cystoid macular edema (CME), which is presumed to resolve
The effects of ganglioside on paclitaxel induced neuropathy were studied in 15 female Wistar rats. The animals were equally divided into 3 groups based on the type of administrated drug. The first (C-group) received an intraperitoneal weekly injection of 1 ml of NSS for five weeks. The second
Inhibition of pancreatic digestive enzyme secretion in the acinar cell is a significant phenomenon which can trigger acute pancreatitis. It has been shown that microtubules are responsible for the intracellular vesicular transport. The effect of taxol, a microtubule stabilizer, was examined in a
OBJECTIVE
To know the effect of neoadjuvant chemotherapy on surgical outcomes (R1 resections, post-operative complications, recurrence and follow up) in Stage IV borderline operable cancers of oral cavity.
METHODS
Patients in group A (n=45) were those who were referred for neoadjuvant chemotherapy
OBJECTIVE
This phase I study of Taxotere (RP 56976, NSC 628503; docetaxel, Rhône-Poulenc Rorer, Antony, France) was undertaken to determine the maximum-tolerated dose (MTD), toxic effects, and basic pharmacokinetics of a day-1 and -8 schedule of this novel semisynthetic product related to Taxol
BACKGROUND
Many ovarian cancer patients will after treatment of the recurrence with cisplatin based therapy enter phase I or II studies with new drugs. Lately, some new agents have shown activity.
METHODS
The review is based on phase II studies mainly and focuses on paclitaxel (taxol).
RESULTS
A
Toxicity is one of the major reasons for failure in drug development. Zebrafish, as an ideal vertebrate model, could also be used to evaluate drug toxicity. In this study, we aimed to show the predictability and highlight novel findings of toxicity in zebrafish model. Seven anticancer compounds,
Thirty-five privately owned 1- to 2-year-old mixed-breed steers and heifers, weighing 340 to 454 kg, died from accidental ingestion of English yew (Taxus baccata). Estimated dosages ranged from 0.36 to 0.70 g of fresh plant/kg of body weight. Clinical signs of poisoning and death began 2 to 3 hours
A 61-year-old women with ovarian carcinoma was treated with surgery followed by 6 cycles of paclitaxel (Taxol) and carboplatin, producing a complete remission. During the course of therapy, she developed diffuse cutaneous sclerosis and thickening along with edema, weight gain and malaise. While
Pathological lung overdistention associated with mechanical ventilation at high tidal volumes (ventilator-induced lung injury; VILI) compromises endothelial cell (EC) barrier leading to development of pulmonary edema and increased morbidity and mortality. We have previously shown involvement of
It is impossible to predict what compounds of pharmacological interest may be present in an unexamined species. The extinction of such species may result, therefore, in the loss of therapeutically significant compounds. The fact that science will never know what has been lost does not lessen the
The taxanes, a new class of anticancer agents, act by promoting the assembly of microtubules and stabilizing formed tubules. Two taxanes, paclitaxel and docetaxel, have clinical activity in epithelial ovarian carcinomas, including tumors with platinum resistance. Toxicities associated with the
Combination antimicrotubule therapy with estramustine phosphate (EMP) and vinblastine has reproducible activity in metastatic hormone-refractory prostate cancer (HRPC) with an objective response rate of 31%. Although paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) by 24-hour infusion